📰 Daptorum Group News
Page 6 - Daptorum Group News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Daptorum Group. Real-time updates on events, politics, business and more.
May 28, 2022
Aptorum Group Limited (NASDAQ:APM – Get Rating) was the target of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 102,500 shares, a decrease of 44.0% from the April 30th total of 183,100 shares. Based on an average trading volume of 115,000 shares, the […]
May 17, 2022
17.05.2022 - Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that Mr. Darren ...
May 17, 2022
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious
May 2, 2022
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
May 2, 2022
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, is pleased to announce the finalized data from
April 29, 2022
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology
April 27, 2022
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in
April 22, 2022
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology
April 22, 2022
Regulatory News: Aptorum Group Limited , a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced that an interview... | April 22, 2022
January 21, 2022
By Michael Dabaie Aptorum Group Ltd. shares rose 30%, to $1.59, premarket after the clinical-stage biopharmaceutical company said the U.S. Food and Drug Administration granted orphan drug... | January 21, 2022